Genmab — Februar 2016
-
jeg tror også vi når 1 mia. $ i 2017
-
US var lukket i går
-
us var lukket mandag - det er ren catch-up
-
Nordea: Roche awarded FDA breakthrough status for CD20 antibody ocrelizumab in PPMS - positive read-across to ofatumumab
-
This is the first time a drug for sclerosis is awarded BTD
-
Medwatch skriver ligesom finans.dk at Humax-TF-ADC kan være nyheder om
-
Novod mener ofa har en fordel i forhold til ocrelizumab da det er en subcu formulation. Til gengæld er Roche ca. 3 år foran i tid
-
MS markedet er +20 milliarder USD per år, så der er rigeligt plads til flere spillere
-
Hvornår kan der komme nyheder om ofa i MS? Hvad betyder subcu formulation?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind